Browsing by Author "Cekerevac, Milica (18433619600)"
Now showing 1 - 7 of 7
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication GSTM1-null and GSTA1-low activity genotypes are associated with enhanced oxidative damage in bladder cancer(2013) ;Savic-Radojevic, Ana (16246037100) ;Djukic, Tatjana (36193753800) ;Simic, Tatjana (6602094386) ;Pljesa-Ercegovac, Marija (16644038900) ;Dragicevic, Dejan (6506794751) ;Pekmezovic, Tatjana (7003989932) ;Cekerevac, Milica (18433619600) ;Santric, Veljko (55598984100)Matic, Marija (58618962300)Objectives: To examine the association between gene variants of the detoxifying and antioxidant enzymes glutathione transferase M1 (GSTM1) and glutathione transferase A1 (GSTA1) and the extent of oxidative damage in patients with transitional cell carcinoma (TCC) of the urinary bladder. Methods: GSTM1 deletion polymorphism was identified by polymerase chain reaction, and the restriction fragment length polymorphism method was used for the single nucleotide polymorphism of GSTA1. Enzyme immunoassay was used to determine markers of DNA (8-hydroxy-2′ -deoxyguanosine, 8-OHdG) and lipid (8-epiprostaglandin F2α) oxidative damage in the urine of 80 TCC patients and 60 age-matched controls. Results: Urinary 8-OHdG and 8-epi-prostaglandin F2α concentrations in TCC patients were significantly higher than in controls (p = 0.043 and 0.001, respectively). GSTM1 and GSTA1 polymorphisms influence vulnerability to both DNA and lipid oxidation, with the GSTM1-null gene variant having a more pronounced effect. A significant effect of combined GSTM1 and GSTA1 genotypes on the extent of oxidative damage was found only for 8-OHdG (p = 0.018). In addition, TCC patients with the most malignant tumors exhibited significantly higher frequencies of GSTM1-null or GSTA1-low activity genotypes, associated with a twofold increase in urinary 8-OHdG concentration (p = 0.044). Conclusions: Our results suggest that absent GSTM1 or reduced GSTA1 antioxidant activity may increase the accumulation of oxidative DNA damage, thereby contributing to the malignant potential of TCC. © W.S. Maney & Son Ltd 2013. - Some of the metrics are blocked by yourconsent settings
Publication GSTM1-null and GSTA1-low activity genotypes are associated with enhanced oxidative damage in bladder cancer(2013) ;Savic-Radojevic, Ana (16246037100) ;Djukic, Tatjana (36193753800) ;Simic, Tatjana (6602094386) ;Pljesa-Ercegovac, Marija (16644038900) ;Dragicevic, Dejan (6506794751) ;Pekmezovic, Tatjana (7003989932) ;Cekerevac, Milica (18433619600) ;Santric, Veljko (55598984100)Matic, Marija (58618962300)Objectives: To examine the association between gene variants of the detoxifying and antioxidant enzymes glutathione transferase M1 (GSTM1) and glutathione transferase A1 (GSTA1) and the extent of oxidative damage in patients with transitional cell carcinoma (TCC) of the urinary bladder. Methods: GSTM1 deletion polymorphism was identified by polymerase chain reaction, and the restriction fragment length polymorphism method was used for the single nucleotide polymorphism of GSTA1. Enzyme immunoassay was used to determine markers of DNA (8-hydroxy-2′ -deoxyguanosine, 8-OHdG) and lipid (8-epiprostaglandin F2α) oxidative damage in the urine of 80 TCC patients and 60 age-matched controls. Results: Urinary 8-OHdG and 8-epi-prostaglandin F2α concentrations in TCC patients were significantly higher than in controls (p = 0.043 and 0.001, respectively). GSTM1 and GSTA1 polymorphisms influence vulnerability to both DNA and lipid oxidation, with the GSTM1-null gene variant having a more pronounced effect. A significant effect of combined GSTM1 and GSTA1 genotypes on the extent of oxidative damage was found only for 8-OHdG (p = 0.018). In addition, TCC patients with the most malignant tumors exhibited significantly higher frequencies of GSTM1-null or GSTA1-low activity genotypes, associated with a twofold increase in urinary 8-OHdG concentration (p = 0.044). Conclusions: Our results suggest that absent GSTM1 or reduced GSTA1 antioxidant activity may increase the accumulation of oxidative DNA damage, thereby contributing to the malignant potential of TCC. © W.S. Maney & Son Ltd 2013. - Some of the metrics are blocked by yourconsent settings
Publication Inflammatory Myofibroblastic Tumour of the Urinary Bladder in a Middle-Aged Man—A Case Report of an Unusual Localization of a Rare Tumour(2023) ;Prijovic, Nebojsa (57219125544) ;Santric, Veljko (55598984100) ;Babic, Uros (57189327647) ;Stankovic, Branko (57970687300) ;Acimovic, Miodrag (6508256624) ;Cekerevac, Milica (18433619600) ;Nikolic, Gorana (56888502300)Cegar, Bojan (55376116500)Inflammatory myofibroblastic tumour (IMT) is a rare tumour with an intermediate biological behaviour. It usually occurs in children and adolescents, primarily in the abdomen or lungs. Histopathologically, IMT consists of spindle cells, i.e., myofibroblasts, and a variable inflammatory component. Localization in the urinary bladder is rare. We are presenting a rare case of IMT in the bladder in a middle-aged man treated by partial cystectomy. A 62-year-old man consulted a urologist because of haematuria and dysuric disturbances. A tumorous mass was detected by an ultrasound in the urinary bladder. CT urography described the tumorous mass at the dome of the urinary bladder measuring 2 × 5 cm. A smooth tumorous mass was cystoscopically observed at the dome of the urinary bladder. Transurethral resection of the bladder tumour was performed. Histopathological analysis of the specimen identified spindle cells with a mixed inflammatory infiltrate; immunohistochemical findings showed positivity for anaplastic lymphoma kinase (ALK), smooth muscle actin (SMA) and vimentin. A histopathological diagnosis of IMT was established. It was decided that the patient would undergo a partial cystectomy. A complete excision of the tumour from the dome of the urinary bladder with surrounding healthy tissue was performed. Histopathological and immunohistochemical findings of the sample confirmed the diagnosis of IMT, without the presence of the tumour at the surgical margins. The postoperative course went smoothly. IMT is a rare tumour in adults, especially localised in the urinary bladder. IMT of the urinary bladder is difficult to distinguish from urinary bladder malignancy both clinically and radiologically, as well as histopathologically. If the location and size of the tumour allow it, bladder-preserving surgeries such as partial cystectomy represent a reasonable modality of operative treatment. © 2023 by the authors. - Some of the metrics are blocked by yourconsent settings
Publication Partial versus radical nephrectomy for pT1a renal cancer in Serbia(2016) ;Janicic, Aleksandar (6505922639) ;Bumbasirevic, Uros (36990205400) ;Pekomezovic, Tatjana (57193536421) ;Cekerevac, Milica (18433619600) ;Acimovic, Miodrag (6508256624) ;Dzamic, Zoran (6506981365)Tulic, Cane (6602213245)Purpose: To assess the treatment outcome ofpTla renal tumors, comparing overall survival (OS) in patients treated with radical nephrectomy (RN) and partial nephrectomy (PN), and to examine the rate of utilization of PN in a tertiary institution in Serbia. Methods: Included were patients treated for pTla kidney tumors with open RN or open PN during 1996-2013. The inclusion criterion was the pathological tumor stage Tla. Exclusion criteria were higher pathological stages, metastatic presentation, or imperative indications for partial nephrectomy. Patients werefollowed-up every 3 to 4 months for the first year after surgery, every 6 months until the 5th year, and annually thereafter. Results: 286 patients were included in the study, and PN was performed in 177 (61.9%) of them, whereas RN was performed in the remaining 109 (38.1%). The median follow-up for the entire group was 42.0 months (interquartile range 74.5). There were no statistically significant differences between groups in cancer-specific survival (CSS) (log-rank=0.506; p=0.477). Patients selected for RN were more likely to be older, symptomatic at presentation, and have larger tumors. There was no statistically significant difference in OS between the two groups (log-rank=2.616; p=0.106). In 1996, 20% of the patients were treated with PN; this number increased to 88% in 2013. Conclusion: We did not find OS advantage for PN compared to RN in the setting of a developing country. The use of PN is increasing and is now utilized for -90% ofpTla renal tumors. - Some of the metrics are blocked by yourconsent settings
Publication Partial versus radical nephrectomy for pT1a renal cancer in Serbia(2016) ;Janicic, Aleksandar (6505922639) ;Bumbasirevic, Uros (36990205400) ;Pekomezovic, Tatjana (57193536421) ;Cekerevac, Milica (18433619600) ;Acimovic, Miodrag (6508256624) ;Dzamic, Zoran (6506981365)Tulic, Cane (6602213245)Purpose: To assess the treatment outcome ofpTla renal tumors, comparing overall survival (OS) in patients treated with radical nephrectomy (RN) and partial nephrectomy (PN), and to examine the rate of utilization of PN in a tertiary institution in Serbia. Methods: Included were patients treated for pTla kidney tumors with open RN or open PN during 1996-2013. The inclusion criterion was the pathological tumor stage Tla. Exclusion criteria were higher pathological stages, metastatic presentation, or imperative indications for partial nephrectomy. Patients werefollowed-up every 3 to 4 months for the first year after surgery, every 6 months until the 5th year, and annually thereafter. Results: 286 patients were included in the study, and PN was performed in 177 (61.9%) of them, whereas RN was performed in the remaining 109 (38.1%). The median follow-up for the entire group was 42.0 months (interquartile range 74.5). There were no statistically significant differences between groups in cancer-specific survival (CSS) (log-rank=0.506; p=0.477). Patients selected for RN were more likely to be older, symptomatic at presentation, and have larger tumors. There was no statistically significant difference in OS between the two groups (log-rank=2.616; p=0.106). In 1996, 20% of the patients were treated with PN; this number increased to 88% in 2013. Conclusion: We did not find OS advantage for PN compared to RN in the setting of a developing country. The use of PN is increasing and is now utilized for -90% ofpTla renal tumors. - Some of the metrics are blocked by yourconsent settings
Publication Renal cancer and Wegener's granulomatosis: A case report(2011) ;Bumbasirevic, Uros (36990205400) ;Dragicevic, Dejan (6506794751) ;Janicic, Aleksandar (6505922639) ;Cemerikic-Martinovic, Vesna (6602432953) ;Cekerevac, Milica (18433619600) ;Aleksic, Vuk (53871123700)Tulic, Cane (6602213245)Wegener's granulomatosis (WG) is a systemic disorder characterized by necrotizing vasculitis involving the respiratory tract, and in most cases, the kidneys. The most common manifestation of WG in the kidneys is segmental necrotizing glomerulonephritis. The presence of a renal mass as a manifestation of WG is rare. We report a patient with WG in whom a CT scan revealed an infiltrating mass in the lower portion of the left kidney. After surgical exploration, we performed an open radical nephrectomy. Histopathology showed clear cell type renal cell carcinoma (RCC). RCC associated with WG has been reported in only a few cases, and in most of them, the diseases started simultaneously, suggesting common pathogenetic pathways. Long-term immunosuppressive treatment is a known risk factor in the development of malignancies, so occurrence of RCC in WG has been proposed as a side effect of cyclophosphamide treatment. Furthermore, it is important to make a differential diagnosis between RCC and pseudotumors in WG as they cannot be distinguished solely on basis of imaging findings. Due to the higher risk of urologic malignancies, more frequent checkups and screening of WG patients should be considered. © 2011 Bumbasirevic et al; licensee BioMed Central Ltd. - Some of the metrics are blocked by yourconsent settings
Publication The Association of Polymorphisms in Genes Encoding Antioxidant Enzymes GPX1 (rs1050450), SOD2 (rs4880) and Transcriptional Factor Nrf2 (rs6721961) with the Risk and Development of Prostate Cancer(2022) ;Djokic, Milica (57215827890) ;Radic, Tanja (35275858300) ;Santric, Veljko (55598984100) ;Dragicevic, Dejan (6506794751) ;Suvakov, Sonja (36572404500) ;Mihailovic, Smiljana (57192397265) ;Stankovic, Vesna (56186752300) ;Cekerevac, Milica (18433619600) ;Simic, Tatjana (6602094386) ;Nikitovic, Marina (6602665617)Coric, Vesna (55584570400)Background and Objectives: Mounting evidence implicates oxidative damage in prostate carcinogenesis, contributing to modifications of macromolecules that drive cellular malignant transformation. Functional single-nucleotide polymorphisms (SNPs) of enzymes involved in redox homeostasis can disrupt pro-oxidant–antioxidant balance, leading to accumulation of reactive oxygen species and oxidative damage. We investigated the potential role of genetic polymorphisms of antioxidant enzymes glutathione peroxidase 1 (GPX1 rs1050450) and superoxide dismutase 2 (SOD2 rs4880) and regulatory antioxidant protein nuclear factor erythroid 2-related factor 2 (Nrf2 rs6721961) in the susceptibility to prostate cancer development (PC) and prognosis. Materials and Methods: We conducted a case–control study consisting of 235 patients with PC and 240 controls. Gene polymorphisms were determined by quantitative polymerase chain reaction (qPCR) and polymerase chain reaction with confronting two-pair primers (PCR-CTTP) methods. Multiple risk models were composed to inspect the separate and mutual effect of multiple genes and in combination with acquired contributory factors on the risk of PC development. Results: Independently, carriers of at least one SOD2*C allele had increased risk of PC development, which was significantly further amplified in advanced statistical models. When tested in combination, individuals with both SOD2*C allele and Nrf2*C/C genotype were also at increased risk of PC development, which was augmented when combined with acquired contributory factors. During the mean 75 ± 25 months of follow-up, investigated gene polymorphisms did not affect overall survival. Conclusion: Our results suggest that these gene polymorphisms could be used as risk biomarkers of PC evolution. © 2022 by the authors.
